Core Viewpoint - A securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its Phase 3 clinical trial for its product DCCR, which is intended for treating hyperphagia in individuals with Prader-Willi syndrome [2][4][5]. Company Overview - Soleno Therapeutics, Inc. is a pharmaceutical company based in Redwood City, California, focused on developing therapies for rare diseases. Its only commercial product is diazoxide choline extended-release tablets (DCCR) [4]. Lawsuit Details - The lawsuit was filed on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025. The case is registered in the United States District Court for the Northern District of California [2][7]. - Investors have until May 5, 2026, to file for lead plaintiff status [2][7]. Allegations - The complaint alleges that Soleno's executives misrepresented the safety of DCCR, downplaying significant safety concerns related to fluid retention in clinical trial participants [5]. - It is claimed that the administration of DCCR posed greater safety risks than disclosed, leading to lower commercial viability and potential adverse events post-launch [5]. - The lawsuit highlights that statements made by Soleno regarding its business and operations were materially false and misleading throughout the class period [5]. Stock Performance - Following the release of financial results on November 4, 2025, Soleno's stock price dropped over 26%, attributed to a report by Scorpion Capital that raised concerns about the DCCR launch trajectory and clinical trial issues [6][8]. Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost. They can seek to be appointed as lead plaintiff or remain an absent class member [3][9].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Driven Brands Holdings Inc. for allegedly making materially false and misleading statements regarding its financial reporting and internal controls, impacting investors who purchased shares between May 9, 2023, and February 24, 2026 [2][4][7]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York, under the case caption Clark v. Driven Brands Holdings Inc., et al, Case No. 1:26-cv-01902 (S.D.N.Y.) [2][4]. - Investors have until May 8, 2026, to file for lead plaintiff status [2][7]. - The complaint alleges that Driven Brands misrepresented financial data, including errors in lease recording, cash balances, and revenue recognition, leading to significant overstatements of cash and revenue [4][5]. Group 2: Financial Impact - On February 25, 2026, Driven Brands announced it would restate its financial statements for fiscal years 2023 and 2024, resulting in a stock price drop of $5.01 per share, or nearly 40%, from $16.61 to $11.60 [5]. - The company disclosed material weaknesses in its internal controls over financial reporting, which contributed to the need for restatement [5]. Group 3: Investor Actions - Investors who have lost money on their investment in Driven Brands are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost [3][9]. - Investors may seek to be appointed as a lead plaintiff representative of the class or choose to remain an absent class member [8][12].

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Picard Medical, Inc. (NYSE: PMI). Shareholders who purchased shares of PMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/picard-medical-inc-loss-submission-form/?id=184365&from=3 CLASS PERIOD: Septembe ...

Core Insights - The Portnoy Law Firm has initiated an investigation into Bausch + Lomb Corporation (BLCO) for possible securities fraud and may file a class action on behalf of investors [1] - BLCO's stock price experienced significant declines following disclosures related to product issues and financial results [2] Group 1: Stock Performance and Investor Impact - BLCO's stock price fell by $1.54, or 9.8%, to close at $14.13 per share over two trading days starting March 28, 2025, due to reports of toxic anterior segment syndrome (TASS) linked to enVista intraocular lenses [2] - A subsequent decline occurred on April 30, 2025, when the stock dropped by $2.16, or 15.7%, closing at $11.56 per share after the company disclosed that the recall would lead to a $55 million revenue impact and a $65 million adjusted EBITDA impact for the year [2] Group 2: Legal Actions and Recovery Efforts - The Portnoy Law Firm is representing investors in claims related to corporate wrongdoing, with a history of recovering over $5.5 billion for affected investors [3]

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Mattel, Inc. and may file a class action on behalf of investors [1]. Financial Performance - Mattel's shares experienced a significant decline, falling by $5.26, or 24.98%, to close at $15.90 on February 11, 2026 [3]. - The decline in share price followed the announcement of fourth quarter and full year 2025 results, where net sales decreased by 1% year over year, and adjusted operating income fell to $620 million, missing previous guidance of 1%-3% growth and $700 million to $750 million [3]. - Management attributed the disappointing results to "trade-related uncertainty," which led retailers to shift orders into the fourth quarter earlier than usual, and noted that efforts to manage owned inventory had a larger-than-expected impact on margins and profitability [3].

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Western Alliance Bancorporation for possible securities fraud, potentially leading to a class action lawsuit on behalf of investors [1]. Group 1: Investigation and Legal Actions - The Portnoy Law Firm is encouraging investors to contact them to discuss their legal rights and options for pursuing claims to recover losses [2]. - The investigation follows a significant stock price decline of $8.52, or 10.81%, closing at $70.32 on October 16, 2025, which was triggered by a lawsuit alleging fraud related to a borrower failing to provide collateral [3]. Group 2: Financial Impact and Issues - The lawsuit claims that the borrower breached a business loan and security agreement by forging title policies for liens on properties associated with multiple loans, raising concerns about the security of the credit relationship [3]. - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving Fulgent Genetics, Inc. and may file a class action on behalf of investors [1]. Group 1: Stock Performance and Financial Impact - Fulgent's stock price dropped by $9.43 per share, or 38.09%, closing at $15.33 per share on February 27, 2026, significantly impacting investors [3]. - The decline in stock value was primarily driven by lower-than-expected guidance for 2026, attributed to the Company's largest customer moving a significant volume of work in-house [3]. - This strategic shift by a key partner fundamentally altered Fulgent's projected revenue streams and growth trajectory, leading to a severe erosion of shareholder value [3]. Group 2: Legal Actions and Investor Support - Investors are encouraged to contact attorney Lesley F. Portnoy for legal rights discussions or to join the case, with options for pursuing claims to recover losses [2]. - The Portnoy Law Firm has a history of recovering over $5.5 billion for aggrieved investors, indicating a strong track record in handling corporate wrongdoing cases [4].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - Investors have until April 3, 2026, to request to lead the case, which is pending in the U.S. District Court for the Northern District of New York [4][10]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of Plug Power investors [4][10]. Group 2: Allegations Against Plug Power - Plug Power is accused of materially overstating the likelihood of receiving a $1.66 billion loan guarantee from the U.S. Department of Energy, which was intended to finance hydrogen production facilities [5]. - The company provides hydrogen fuel cell solutions and develops infrastructure for hydrogen production [5]. Group 3: Stock Performance and Impact - Plug Power's stock dropped 6.3% on October 7, 2025, following the abrupt departure of its CEO and President [6]. - A subsequent announcement on November 10, 2025, regarding the suspension of activities under the DOE loan program led to a 3.4% decline in stock price [7]. - On November 14, 2025, news of the suspension of plans to construct hydrogen facilities resulted in a significant 17.6% drop in stock price [8].

Core Viewpoint - PennyMac Financial Services, Inc. is under investigation for potential violations of federal securities laws related to its mortgage recapture efforts as interest rates declined [1][2][3]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is investigating whether PennyMac misrepresented its ability to recapture customers refinancing their mortgages during a period of declining interest rates [3]. - The investigation follows PennyMac's claims of improved recapture rates, which may not align with actual performance [2]. Group 2: Stock Performance - On January 29, 2026, PennyMac reported disappointing financial results for Q4 2025, revealing that increased origination capacity did not translate into expected refinancing opportunities due to heightened competition [4]. - Following the earnings call, PennyMac's stock price dropped over 37%, from $140.70 per share to as low as $93.50 per share on January 30, 2026 [4].

Core Viewpoint - Wealthfront Corporation is under investigation for potential violations of federal securities laws, particularly concerning misleading statements made during its IPO process [1][3]. Group 1: Company Overview - Wealthfront is an online financial advisor that utilizes automated tools to provide investment and financial advice [2]. - The company completed its initial public offering (IPO) on December 12, 2025, offering over 34 million shares at a price of $14.00 per share [2]. Group 2: Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Wealthfront made false and misleading statements to investors, especially in the IPO offering materials [3]. - The investigation is prompted by significant changes in the company's financial performance following its IPO [3]. Group 3: Financial Performance and Stock Impact - On January 12, 2026, Wealthfront reported its first quarterly results as a public company, revealing net deposit outflows of $208 million, a significant decline from the $874 million inflows during the same period the previous year [4]. - Following the earnings report, Wealthfront's stock price dropped by $2.12 per share, nearly 17%, from $12.59 to $10.47 on January 13, 2026 [4]. - CEO David Fortunato attributed the decline in deposits to falling interest rates and highlighted the strategic importance of the company's new home-lending business [4].